Q

QUEST Research Institute | Farmington Hills, MI

Research site
(Unclaimed)
Location
28595 Orchard Lake Road, Suite 301, Farmington Hills, Michigan, United States of America
Site insights

Top conditions

Parkinson Disease (38 trials)

Alzheimer Disease (14 trials)

Atrophy (6 trials)

Shy-Drager Syndrome (6 trials)

Multiple System Atrophy (6 trials)

Top treatments

APL-130277
Carbidopa
Levodopa
CVN424
LY3002813
Prasinezumab
Gantenerumab
ND0612
Donanemab
ABBV-916

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

25 of 74
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease (PD)....

Active, not recruiting
Parkinson Disease
Drug: NLY01
Drug: Vehicle

This is a multi-center, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa (LD/CD) delivered via a pump system as a...

Active, not recruiting
Parkinson's Disease
Drug: ND0612

This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and...

Enrolling
Multiple System Atrophy (MSA)
Drug: Placebo
Drug: ONO-2808

This is a Phase 2a study to assess the safety and tolerability of TPN-101 patients with PSP.

Active, not recruiting
Progressive Supranuclear Palsy
Drug: Placebo
Drug: TPN-101, 100 mg/day

This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptom...

Enrolling
Alzheimer's Disease
Mental Disorders
Drug: Donanemab
Drug: Placebo

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Cli...

Enrolling
Alzheimer's Disease (AD)
Drug: Placebo
Drug: ABBV-916

The purpose of the study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) prof...

Enrolling
Spasticity
Biological: IPN10200
Drug: Placebo

This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP385 in the treatm...

Active, not recruiting
Essential Tremor
Drug: JZP385
Other: Placebo

In this study, researchers will learn more about a study drug called BIIB122 in participants with early-stage Parkinson's disease (PD). In this study...

Enrolling
Parkinson Disease
Drug: BIIB122
Drug: BIIB122-Matching Placebo

Researchers are looking for a better way to help people with known or suspected brain or spinal cord-related problems scheduled for a "contrast-enhan...

Enrolling
Central Nervous System Pathology
Contrast Enhancement in Magnetic Resonance Imaging
Drug: Gadobutrol
Drug: Gadoquatrane (BAY1747846)

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab...

Active, not recruiting
Parkinsons Disease
Drug: Prasinezumab
Drug: Placebo

This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX00...

Active, not recruiting
Parkinson's Disease
Drug: RO7046015
Drug: Placebo

The primary objective of this study is to evaluate the safety and tolerability of single and multiple doses of BIIB094 administered via intrathecal (...

Active, not recruiting
Parkinson's Disease
Drug: Placebo
Drug: BIIB094

This is a multi-center, randomized, double blind, adaptive, parallel-group, placebo controlled Phase 1b study to evaluate the safety, tolerability, p...

Enrolling
Parkinson Disease
Drug: RO7486967
Drug: Placebo

ORION Trial is a trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of a rand...

Enrolling
PSP
Neurodegenerative Diseases
Other: Placebo
Drug: AMX0035

The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple-ascending intra...

Enrolling
Alzheimers Disease
Drug: Placebo
Drug: RO7126209

This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD)....

Enrolling
Parkinson's Disease
Drug: Placebo
Drug: CVN424 150 mg

This is a multi-center, randomized, double-blind, double-dummy, active controlled clinical Study. Following a screening period, eligible subjects wil...

Active, not recruiting
Parkinson's Disease
Combination Product: ND0612 Solution for SC infusion
Drug: Placebo for Oral IR-LD/CD

The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical mea...

Enrolling
Parkinson's Disease
Drug: BIA 28-6156 60 mg
Drug: BIA 28-6156 10 mg

Trial sponsors

Roche logo

Roche (6 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems